Motif Plunges As FDA Demands New Iclaprim Study
Executive Summary
The UK biotech is in dire need of further funding after US regulators requested an additional clinical trial for its much-delayed skin infection antibiotic.
You may also be interested in...
New Trial With Longer Liver Elevation Needed For Iclaprim, US FDA Tells Motif Bio
Longer follow-up is part of regulatory path forward, the struggling antibiotics firm says after meeting with US FDA to discuss complete response letter.
Money Too Tight To Mention At Motif After Iclaprim 'No' From FDA
Hit with a complete response letter from the US FDA for its antibiotic to treat ABSSSI, Motif needs to raise funds and fast to stay afloat and prepare a meeting package to discuss the next steps for iclaprim with the agency.
Keeping Track: Rebuff Of Iclaprim Creates Early Pileup Of CRLs For Novel Drugs
The latest drug development news and highlights from our US FDA Performance Tracker.